Literature DB >> 23108563

Adult moyamoya after revascularization.

Bradley A Gross1, Rose Du.   

Abstract

BACKGROUND: Although cerebral revascularization is an accepted treatment for moyamoya, the precise impact of direct or indirect bypass methods on subsequent event rates is infrequently addressed in adult cohorts.
METHODS: We reviewed 45 consecutive adults with 69 hemispheres affected by moyamoya. We evaluated stroke and hemorrhage rates prior to and following revascularization.
RESULTS: Direct revascularization was performed for 35 hemispheres (51 %) in 29 patients (64 %). The annual stroke, hemorrhage and overall event rates in this cohort diminished from 8.9 %, 2.0 %, and 11 % per hemisphere-year to 4.5 %, 0 %, and 4.5 % per hemisphere-year after treatment, respectively (p = 0.06). Excluding perioperative events, no events occurred over 41.1 hemisphere-years of follow-up (p = 0.0017). After a mean clinical follow-up period of 1.3 years, 72 % of patients were improved, 24 % the same, and 3 % worse in this cohort. Indirect revascularization was performed for 18 hemispheres (26 %) in 13 patients (29 %). The annual stroke, hemorrhage and overall event rates were 13 %, 0 %, and 13 % per hemisphere-year prior to treatment, and 6.8 %, 4.5 %, and 11 % per hemisphere-year after treatment, respectively (p = 0.67). Excluding perioperative events, the overall annual event rate was 7.1 % (p = 0.69). After a mean clinical follow-up of 2.7 years, 46 % of patients were improved, 38 % were the same and 15 % were worse.
CONCLUSION: Direct revascularization is the optimal choice to prevent subsequent events in adult patients with moyamoya. A favorable impact of indirect revascularization was less clear in this cohort, and should be reserved for patients with an inadequate donor vessel.

Entities:  

Mesh:

Year:  2012        PMID: 23108563     DOI: 10.1007/s00701-012-1545-4

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  8 in total

1.  Treatment course and outcomes after revascularization surgery for moyamoya disease in adults.

Authors:  Amanda Kahn; Gurmeen Kaur; Laura Stein; Stanley Tuhrim; Mandip S Dhamoon
Journal:  J Neurol       Date:  2018-09-08       Impact factor: 4.849

2.  Moyamoya disease and moyamoya syndrome in Ireland: patient demographics, mode of presentation and outcomes of EC-IC bypass surgery.

Authors:  Ronan J Doherty; John Caird; Darach Crimmins; Peter Kelly; Sean Murphy; Christopher McGuigan; Niall Tubridy; Mary D King; Bryan Lynch; David Webb; Desmond O'Neill; Dominick J H McCabe; Peter Boers; Mary O'Regan; Joan Moroney; David J Williams; Simon Cronin; Mohsen Javadpour
Journal:  Ir J Med Sci       Date:  2020-06-19       Impact factor: 1.568

Review 3.  Surgical Treatment of Adult Moyamoya Disease.

Authors:  Si Un Lee; Chang Wan Oh; O-Ki Kwon; Jae Seung Bang; Seung Pil Ban; Hyoung Soo Byoun; Tackeun Kim
Journal:  Curr Treat Options Neurol       Date:  2018-05-28       Impact factor: 3.598

Review 4.  Endovascular treatment of symptomatic moyamoya.

Authors:  Bradley A Gross; Ajith J Thomas; Kai U Frerichs
Journal:  Neurosurg Rev       Date:  2014-04-03       Impact factor: 3.042

Review 5.  Moyamoya Disease: Treatment and Outcomes.

Authors:  Tackeun Kim; Chang Wan Oh; Jae Seung Bang; Jeong Eun Kim; Won-Sang Cho
Journal:  J Stroke       Date:  2016-01-29       Impact factor: 6.967

6.  Recurrent Bleeding in Hemorrhagic Moyamoya Disease : Prognostic Implications of the Perfusion Status.

Authors:  Kyung-Il Jo; Min Soo Kim; Je Young Yeon; Jong-Soo Kim; Seung-Chyul Hong
Journal:  J Korean Neurosurg Soc       Date:  2016-02-29

7.  Resolution of bilateral moyamoya associated collateral vessel aneurysms: Rationale for endovascular versus surgical intervention.

Authors:  Sepideh Amin-Hanjani; Sean Goodin; Fady T Charbel; Ali Alaraj
Journal:  Surg Neurol Int       Date:  2014-06-19

8.  The Efficacy of Surgical Treatment for the Secondary Prevention of Stroke in Symptomatic Moyamoya Disease: A Meta-Analysis.

Authors:  Cong Qian; Xiaobo Yu; Jianru Li; Jingyin Chen; Lin Wang; Gao Chen
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.